Firmaet har informeret CHMP om, at der ikke er konsekvenser for patienter, der på nuværende tidspunkt deltager i kliniske undersøgelser eller programmer for specialudlevering af Valdoxan/ Thymanax.
The Company has informed the CHMP that there are no consequences on patients currently included in clinical trials or compassionate use programmes with Valdoxan/ Thymanax.